The eFlow® was developed in partnership with PARI GmbH, applying TTP’s proprietary electronic atomiser technology, TouchSpray™, to create an innovative inhalation system for the treatment of respiratory diseases.
Biosensors and Medical Devices, Healthcare, Pharma and drug delivery
You breathe in. You breathe out. This happens about 20,000 times a day, without a second thought. But if you have cystic fibrosis, chronic asthma, or another respiratory disease, it’s a different story. You may need a regular dose of drugs delivered straight into your lungs, just to keep you alive.
Deep lung penetration requires a highly controlled droplet size — too small and the droplets are exhaled, too large and they’ll land in the back of the throat.
TTP’s challenge was to find a better way to deliver liquid-phase drugs directly into the lungs, one that would increase drug efficacy and eliminate propellant gases.
The solution was TouchSpray™, a chamberless, planar nozzle plate driven by a piezoelectric actuator. The inertial transfer mechanism generates a highly defined aerosol of liquid droplets at the touch of a button.
The invention of this breakthrough technology ultimately led to the global launch of the PARI eFlow® electronic nebuliser — a new inhaler that cuts patient treatment time by an amazing 50%. The drug delivery technology used in the PARI eFlow® electronic nebuliser enables liquid medication to be absorbed through the lungs with as much as 90% efficacy.
What makes the Pari eFlow® different?
- Reduces treatment time by more than 50%
- Silent, discreet operation
- Battery-powered and easily portable
- Interchangeable spray heads allow easy cleaning
- More reliable and serviceable than traditional compressor-based systems
- Designed for use with all inhalation medications approved in Europe.